| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD200 |
| Uniprot No | P41217 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-124aa |
| 氨基酸序列 | VVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHG VVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFN |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CD200重组蛋白的代表性文献摘要(文献名称、作者及核心内容概括)：
---
1. **文献名称**: *CD200 immune checkpoint reversal: A novel approach to enhance the anti-tumor immune response*
**作者**: Smith et al.
**摘要**: 该研究探讨了CD200重组蛋白(rCD200)在肿瘤免疫逃逸中的作用，证明其通过与CD200受体(CD200R)结合抑制巨噬细胞和T细胞的活性。研究通过阻断CD200/CD200R通路，可增强抗肿瘤免疫应答，为癌症免疫治疗提供新策略。
---
2. **文献名称**: *Recombinant CD200 protein attenuates inflammation in a murine sepsis model*
**作者**: Zhang Y. et al.
**摘要**: 在小鼠脓毒症模型中，重组CD200蛋白通过抑制促炎细胞因子(如TNF-α、IL-6)释放，显著减轻全身炎症反应。机制研究表明，CD200通过调节髓系细胞功能，维持免疫稳态，提示其在脓毒症治疗中的潜在应用。
---
3. **文献名称**: *Structural and functional characterization of recombinant human CD200 fusion protein*
**作者**: Wang L. et al.
**摘要**: 本研究解析了重组人源CD200-Fc融合蛋白的结构，并通过体外实验验证其与CD200R的结合活性。结果显示，该蛋白可有效抑制树突状细胞的活化，为开发基于CD200的免疫调节疗法提供分子基础。
---
**备注**：文献为虚拟概括，实际研究需根据具体需求检索PubMed等数据库获取。
CD200 recombinant protein is a biologically engineered molecule derived from the CD200 glycoprotein, a type-1 transmembrane protein belonging to the immunoglobulin superfamily. Naturally expressed on various cell types, including neurons, endothelial cells, and immune cells, CD200 interacts with its receptor CD200R, primarily found on myeloid cells such as macrophages and microglia. This interaction delivers immunosuppressive signals that regulate inflammatory responses and maintain immune homeostasis. The CD200-CD200R axis plays a critical role in dampening excessive immune activation, preventing tissue damage, and promoting tolerance in settings like autoimmune diseases, transplantation, and cancer.
Recombinant CD200 protein is typically produced using expression systems (e.g., mammalian, insect, or bacterial cells) to generate soluble forms lacking the transmembrane domain. This allows researchers to study CD200's immunomodulatory functions in vitro or in vivo without membrane anchoring. Applications include investigating immune checkpoint mechanisms, exploring therapeutic strategies for inflammatory disorders, and modulating macrophage/microglial activity in neurodegenerative diseases. In cancer research, CD200 recombinant protein is studied for its dual role: while it may suppress antitumor immunity by inhibiting effector cells, it also holds potential for mitigating graft-versus-host disease (GVHD) in transplantation.
Current studies focus on optimizing its structure for enhanced receptor binding or stability and evaluating its therapeutic efficacy in preclinical models. Challenges include balancing its immunosuppressive effects with desired clinical outcomes and understanding tissue-specific responses. Overall, CD200 recombinant protein serves as a vital tool for dissecting immune regulation and developing targeted immunotherapies.
×
